Key Details
Price
$646.45Annual ROE
-8.54%Beta
0.49Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
This is a comparison of how argenx SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have done in relation to their industry this year.
Argenx (ARGX) shares have begun to rise and may keep increasing soon, based on positive changes in earnings forecasts.
This is a comparison of how argenex SE (ARGX) and Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) have done in relation to their industry this year.
The company announced that its estimated global product net sales for the entire year of 2024 reached $2.2 billion, which includes $737 million in sales from the fourth quarter.
VYVDURA ® has received approval for self-injection at home in Japan for the treatment of generalized myasthenia gravis and CIDP.
On November 26, 2024, in Amsterdam, the Netherlands, argenx (Euronext & Nasdaq: ARGX), a worldwide immunology company focused on helping those with serious autoimmune diseases, shared that its management team will take part in several investor conferences in December.
Phase 2 data has shown that efgartigimod SC is a promising treatment for myositis, and enrollment will proceed to Phase 3 for all three subtypes (IMNM, ASyS, DM) in the ALKIVIA study. This treatment could be the first targeted option for myositis patients who have few alternatives. Argenx SE, a global immunology company, announced this decision after reviewing the initial results from the Phase 2 study.
Argenx (ARGX) shares have begun to rise and could keep increasing soon, based on positive changes in earnings forecasts.
This is a comparison of how argenx SE (ARGX) and Novartis (NVS) have done in relation to their industry this year.
On November 5, 2024, in Amsterdam, the Netherlands, argenx (Euronext & Nasdaq: ARGX), a worldwide immunology company focused on enhancing the lives of those with serious autoimmune diseases, shared that its management team will take part in several investor conferences this November.
FAQ
- What is the ticker symbol for argenx SE?
- Does argenx SE pay dividends?
- What sector is argenx SE in?
- What industry is argenx SE in?
- What country is argenx SE based in?
- When did argenx SE go public?
- Is argenx SE in the S&P 500?
- Is argenx SE in the NASDAQ 100?
- Is argenx SE in the Dow Jones?
- When was argenx SE's last earnings report?
- When does argenx SE report earnings?
- Should I buy argenx SE stock now?